Le drame de la thalidomide, un médicament sans frontières

ope

Surgical versus conservative management of Type III acromioclavicular dislocation: a systematic review

The management of Type III acromioclavicular (AC) dislocations is still controversial. We wished to compare the rate of recurrence and outcome scores of operative versus non-operative treatment of patients with Type III AC dislocations

YIELD AND QUALITY OF MAIZE GROWN ON A LOAMY SOIL AMENDED WITH NATURAL CHABAZITE ZEOLITITE

The agronomic use of natural zeolite is widely supported by several works. However, almost all are focused on the application of the clinoptilolite as slow plant-nutrient fertilizer and soil conditioner. Our study describes the first comprehensive study on the effects of a Italian chabazite-bearing zeolitite (rocks containing more than 50% of zeolites) on a maize cultivation. The objective was to determine the effects of applying zeolitite on (i) Zea mays yield and quality, under two irrigation regimes and (ii) check if it can improve the efficiency of urea fertilization on a loamy soil in an open experimental field of Italy. The production and quality of the corn grown in the traditional way was compared with that of the plots treated with two different amounts of zeolitite (4 and 8 Kg/m2) and each treatment was monitored both in irrigated and not-irrigated conditions. The measurements of chlorophyll and those related to the morphological features of the plants show suffering conditions of the corn plants in not-irrigated conditions. Furthermore we show that the plants grown with zeolitite and fertilized with less urea have produced the same amounts of corn plants fertilized with traditional contents of urea

KEAP1 and TP53 frame genomic, evolutionary and immunological subtypes of lung adenocarcinoma with different sensitivity to immunotherapy

The connection between driver mutations and efficacy of immune-checkpoint inhibitors (ICIs) is the focus of intense investigations. In lung adenocarcinoma (LUAD), KEAP1/STK11 alterations have been tied to immunoresistance. Nevertheless, the heterogeneity characterizing immunotherapy efficacy suggests the contribution of still unappreciated events

Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme

ObjectiveTo report the safety and efficacy results of patients enrolled in the Italian Nivolumab Renal Cell Cancer Expanded Access Programme. Patients and MethodsPatients with metastatic renal cell cancer (mRCC) previously treated with agents targeting the vascular endothelial growth factor pathway were eligible to receive nivolumab 3mg/kg once every 2weeks. Patients included in the analysis had received 1 dose of nivolumab and were monitored for adverse events (AEs) using Common Terminology Criteria for Adverse Events (CTCAE) v.4.0. ResultsA total of 389 patients were enrolled between July 2015 and April 2016, of whom 18% were aged 75years, 6.7% had non-clear cell RCC, 49.6% had bone and 8.2% brain metastases, and 79% had received 2 previous lines of therapy. The most common any-grade treatment-related AEs were fatigue (13%) and rash (9%). Twenty-two patients (5.7%) discontinued treatment because of AEs. There were no treatment-related deaths. The objective response rate was 23.1%. At a median follow-up of 12months, the median progression-free survival was 4.5months (95% confidence interval 3.7-6.2) and the 12-month overall survival rate was 63%. Similar survival rates were reported among patients with non-clear-cell histology, elderly patients, those with bone and/or brain metastases, and those who had received prior first-line sunitinib or pazopanib, or prior everolimus. ConclusionThe safety and efficacy observed were consistent with those reported in the pivotal Checkmate 025 trial. Results in patients with non-clear-cell mRCC who were elderly, pretreated with everolimus, and had bone and/or brain metastases encourage the use of nivolumab in these categories of patient